Table 2.
Demographic and clinical characteristics of trial participants
| FCM (n = 24) | Saline (n = 25) | ||
|---|---|---|---|
| Age, years (SD) | 61.1 (10.8) | 64 (10) | |
| Gender (n, %) | Male | 18 (75) | 20 (80) |
| Ethnicity (n, %) | Chinese | 10 (41.7) | 15 (60) |
| Indian | 3 (12.5) | 4 (16) | |
| Malay | 10 (41.7) | 6 (24) | |
| Other | 1 (4.2) | 0 (0) | |
| Weight, kg (SD) | 73.1 (13.5) | 64.9 (12.6) | |
| Height, cm (SD) | 161.0 (8.4) | 162.8 (9.7) | |
| Medication (n, %) | Diuretics | 21 (87.5) | 23 (92) |
| ACEI | 11 (45.8) | 8 (32) | |
| ARB | 8 (33.3) | 5 (20) | |
| Beta‐blocker | 24 (100) | 20 (80) | |
| Antiplatelet | 14 (58.3) | 20 (80) | |
| MRA | 7 (29.2) | 10 (40) | |
| Lipid lowering | 22 (91.7) | 21 (84) | |
| Iron supplement | 15 (62.5) | 12 (48) | |
| Co‐morbidities (n, %) | Type 2 DM | 15 (62.5) | 15 (60) |
| Hypertension | 21 (87.5) | 18 (72) | |
| Hyperlipidaemia | 20 (83.3) | 20 (80) | |
| Previous AMI | 12 (50) | 13 (52) | |
| Current smoking | 5 (20.8) | 5 (20) | |
| LVEF, % (SD) | 38.8 (17.5) | 33.2 (14.8) | |
| HFpEF (n, %) | 9 (39.1) | 4 (16) | |
| 6MWT distance, m (SD) | 252.4 (122.7) | 242.6 (66.8) | |
| Quality of life measures | KCCQ Overall | 50.0 (17.7) | 51.2 (14.5) |
| VAS score | 6.4 (1.6) | 5.7 (1.0) | |
| Laboratory measurements | Hb, g/dL (SD) | 11.6 (1.9) | 13.1 (1.3) |
| Ferritin, ng/mL (SD) | 91.4 (80.4) | 84.1 (63.7) | |
| TSAT, % (SD) | 15.7 (10.1) | 13.9 (6.8) |
ACEI, angiotensin‐converting enzyme inhibitor; AMI, acute myocardial infarction; ARB, angiotensin receptor blocker; DM, diabetes mellitus; FCM, ferric carboxymaltose; Hb, haemoglobin; HFpEF, heart failure with preserved ejection fraction; KCCQ, Kansas City Cardiomyopathy Questionnaire; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association; SD, standard deviation; 6MWT, 6‐minute walk test; TSAT, transferrin saturation; VAS, Visual Analogue Score.